Suppr超能文献

一种新型三元共聚物纳米颗粒成孔剂作为塞来昔布在控释无定形固体分散体微丸中的内部重结晶抑制剂:实验研究与分子动力学分析

An emerging terpolymeric nanoparticle pore former as an internal recrystallization inhibitor of celecoxib in controlled release amorphous solid dispersion beads: Experimental studies and molecular dynamics analysis.

作者信息

Lugtu-Pe Jamie Anne, Zhang Xuning, Mirzaie Sako, Chang Hao Han R, Al-Mousawi Nour, Chen Kuan, Li Yongqiang, Kane Anil, Bar-Shalom Daniel, Wu Xiao Yu

机构信息

Advanced Pharmaceutics and Drug Delivery Laboratory, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto M5S 3M2, Canada.

Candoo Pharmatech Company Inc., Mississauga L5N 5M1, Canada.

出版信息

Acta Pharm Sin B. 2024 Jun;14(6):2669-2684. doi: 10.1016/j.apsb.2024.03.026. Epub 2024 Mar 22.

Abstract

Solid oral controlled release formulations feature numerous clinical advantages for drug candidates with adequate solubility and dissolution rate. However, most new chemical entities exhibit poor water solubility, and hence are exempt from such benefits. Although combining drug amorphization with controlled release formulation is promising to elevate drug solubility, like other supersaturating systems, the problem of drug recrystallization has yet to be resolved, particularly within the dosage form. Here, we explored the potential of an emerging, non-leachable terpolymer nanoparticle (TPN) pore former as an internal recrystallization inhibitor within controlled release amorphous solid dispersion (CRASD) beads comprising a poorly soluble drug (celecoxib) reservoir and insoluble polymer (ethylcellulose) membrane. Compared to conventional pore former, polyvinylpyrrolidone (PVP), TPN-containing membranes exhibited superior structural integrity, less crystal formation at the CRASD bead surface, and greater extent of celecoxib release. All-atom molecular dynamics analyses revealed that in the presence of TPN, intra-molecular bonding, crystal formation tendency, diffusion coefficient, and molecular flexibility of celecoxib were reduced, while intermolecular H-bonding was increased as compared to PVP. This work suggests that selection of a pore former that promotes prolonged molecular separation within a nanoporous controlled release membrane structure may serve as an effective strategy to enhance amorphicity preservation inside CRASD.

摘要

对于具有足够溶解度和溶出速率的候选药物而言,固体口服控释制剂具有众多临床优势。然而,大多数新化学实体的水溶性较差,因此无法享受这些优势。尽管将药物非晶化与控释制剂相结合有望提高药物溶解度,但与其他过饱和系统一样,药物重结晶问题仍有待解决,尤其是在剂型内部。在此,我们探索了一种新型的、不可浸出的三元共聚物纳米颗粒(TPN)成孔剂作为内部重结晶抑制剂的潜力,该抑制剂存在于控释无定形固体分散体(CRASD)微丸中,该微丸包含难溶性药物(塞来昔布)储库和不溶性聚合物(乙基纤维素)膜。与传统成孔剂聚乙烯吡咯烷酮(PVP)相比,含TPN的膜表现出更好的结构完整性、CRASD微丸表面更少的晶体形成以及更大程度的塞来昔布释放。全原子分子动力学分析表明,在TPN存在的情况下,与PVP相比,塞来昔布的分子内键合、晶体形成趋势、扩散系数和分子柔韧性降低,而分子间氢键增加。这项工作表明,选择一种能促进纳米多孔控释膜结构内分子长时间分离的成孔剂,可能是增强CRASD内部无定形状态保持的有效策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd5e/11143779/0ffaac3bcc36/ga1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验